Judith Matthews - Iterum Therapeutics Chief Officer
| ITRM Stock | USD 1.97 0.33 14.35% |
Executive
Ms. Judith M. Matthews serves as Chief Financial Officer of the Company. Judy Matthews has served as Chief Financial Officer since late 2015 when the company was formed. From 2012 to 2015, Ms. Matthews served as VP of Finance at Durata Therapeutics, Inc. until its acquisition by Actavis plc. From 2009 to 2012, Ms. Matthews was Head of Financial Planning Analysis at Bally Total Fitness. From 2004 to 2008, Ms. Matthews served as VP of Finance for the Sterno Group, a subsidiary of Blyth, Inc
| Age | 54 |
| Address | Fitzwilliam Court, Dublin, Ireland, D02 YW24 |
| Phone | 353 1 669 4820 |
| Web | https://www.iterumtx.com |
Judith Matthews Latest Insider Activity
Tracking and analyzing the buying and selling activities of Judith Matthews against Iterum Therapeutics stock is an integral part of due diligence when investing in Iterum Therapeutics. Judith Matthews insider activity provides valuable insight into whether Iterum Therapeutics is net buyers or sellers over its current business cycle. Note, Iterum Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Iterum Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Judith Matthews over a year ago Acquisition by Judith Matthews of 6666 shares of Iterum Therapeutics subject to Rule 16b-3 |
Iterum Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.7335) % which means that it has lost $0.7335 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (5.5568) %, meaning that it created substantial loss on money invested by shareholders. Iterum Therapeutics' management efficiency ratios could be used to measure how well Iterum Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 12th of December 2024, Return On Equity is likely to grow to 6.29, while Return On Tangible Assets are likely to drop (1.53). At this time, Iterum Therapeutics' Other Current Assets are very stable compared to the past year. As of the 12th of December 2024, Total Current Assets is likely to grow to about 47 M, while Net Tangible Assets are likely to drop about 14.9 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Sandra Vedrick | Revelation Biosciences | N/A | |
| Sean Proehl | Dermata Therapeutics | N/A | |
| Karen Quarford | Vincerx Pharma | N/A | |
| Kristi Sarno | Ibio Inc | N/A | |
| MPH MD | Tonix Pharmaceuticals Holding | N/A | |
| Karen Brunke | Jaguar Animal Health | 72 | |
| Catherine MS | Citius Pharmaceuticals | N/A | |
| Nikolas Burlew | Citius Pharmaceuticals | N/A | |
| Andrew Taubman | Adial Pharmaceuticals | N/A | |
| Eugene Scavola | Verrica Pharmaceuticals | N/A | |
| Felipe Duran | Ibio Inc | 45 | |
| Peter Hodge | Jaguar Animal Health | N/A | |
| Thomas Englese | Tonix Pharmaceuticals Holding | 50 | |
| Ilanit Allen | Citius Pharmaceuticals | N/A | |
| Christopher Hayes | Verrica Pharmaceuticals | 60 | |
| Marc JD | Ibio Inc | N/A | |
| Steven RPh | Vincerx Pharma | 63 | |
| Sina Bavari | Tonix Pharmaceuticals Holding | N/A | |
| Robyn Hunter | Fortress Biotech | 62 | |
| James MBA | Tonix Pharmaceuticals Holding | N/A | |
| Myron MD | Citius Pharmaceuticals | 64 | |
Management Performance
| Return On Equity | -5.56 | ||||
| Return On Asset | -0.73 |
Iterum Therapeutics PLC Leadership Team
Elected by the shareholders, the Iterum Therapeutics' board of directors comprises two types of representatives: Iterum Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Iterum. The board's role is to monitor Iterum Therapeutics' management team and ensure that shareholders' interests are well served. Iterum Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Iterum Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Sailaja MD, Chief Officer | ||
| Tom Loughman, Senior Operations | ||
| Steven MD, Senior Development | ||
| Louise Barrett, Senior Secretary | ||
| Corey Fishman, CEO, Director | ||
| Michael MD, Strategic Director | ||
| Judith Matthews, Chief Officer |
Iterum Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Iterum Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -5.56 | ||||
| Return On Asset | -0.73 | ||||
| Current Valuation | 62.42 M | ||||
| Shares Outstanding | 27.52 M | ||||
| Shares Owned By Insiders | 1.81 % | ||||
| Shares Owned By Institutions | 8.98 % | ||||
| Number Of Shares Shorted | 2.52 M | ||||
| Price To Earning | 16.21 X | ||||
| Price To Book | 6.03 X | ||||
| Price To Sales | 1,350 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Iterum Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Iterum Therapeutics. If investors know Iterum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Iterum Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.76) | Quarterly Revenue Growth (1.00) | Return On Assets (0.73) | Return On Equity (5.56) |
The market value of Iterum Therapeutics PLC is measured differently than its book value, which is the value of Iterum that is recorded on the company's balance sheet. Investors also form their own opinion of Iterum Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Iterum Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Iterum Therapeutics' market value can be influenced by many factors that don't directly affect Iterum Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Iterum Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Iterum Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Iterum Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.